Related Experiment Video
Updated: May 6, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia
Jyoti Malhotra1, Marina Kremyanskaya1, Emily Schorr1
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Introduction:
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and are characterized by clonal proliferation of hematopoietic cells in the bone marrow. There are numerous case reports and reviews reporting patients with coexisting MPN and plasma-cell disease such as multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).
Methods:
We report 15 patients treated at our institution over a 5-year period (January 2008 to December 2012) with a diagnosis of both an MPN and MGUS or MM. We also reviewed and summarized published case reports and studies describing the coexistence of these two disease entities.
Results:
Most patients (12/15) had an MPN diagnosis made before or at the same time as the MGUS/MM diagnosis. Eventually, 2 patients developed a lymphoid leukemia, 1 patient developed lymphoma, and 1 patient developed acute myeloid leukemia, raising the question of whether patients with coexistence of myeloid- and lymphoid-derived neoplasms are more prone to leukemic or lymphomatous transformation. We did not find any treatment-related effect that could have contributed to the development of coexisting MGUS or MM and MPN. Of the 7 patients with an abnormal karyotype, 3 patients had trisomy 8.
Conclusion:
At present, management strategies are aimed at treating the MPN and regularly monitoring the MGUS for transformation to an overt plasma-cell malignancy. However, for patients who develop overt MM, management is focused more on treating the myeloma and monitoring the MPN. It has not yet been definitively shown that these 2 entities arise from a common-ancestor hematopoietic stem cell.
Insights
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) can coexist with plasma-cell disorders like multiple myeloma (MM). Management focuses on treating the MPN and monitoring for MM transformation.
Area of Science:
- Hematology
- Oncology
Background:
- Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), involve clonal hematopoietic cell proliferation.
- Coexistence of MPNs with plasma-cell diseases such as multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) has been reported.
Observation:
- A study reviewed 15 patients diagnosed with both MPN and MGUS or MM over a 5-year period.
- The majority of patients (12/15) received their MPN diagnosis before or concurrently with their MGUS/MM diagnosis.
- No treatment-related effects were identified as contributing to the development of coexisting MGUS/MM and MPN.
Findings:
- Two patients developed lymphoid leukemia, one developed lymphoma, and one developed acute myeloid leukemia, prompting investigation into increased transformation risk in coexisting myeloid and lymphoid neoplasms.
- Among 7 patients with abnormal karyotypes, 3 exhibited trisomy 8.
- The origin of these coexisting conditions from a common hematopoietic stem cell remains unproven.
Implications:
- Current management involves treating the MPN and monitoring MGUS for progression to overt malignancy.
- For patients with overt MM, treatment prioritizes myeloma management while monitoring the MPN.
- Further research is needed to elucidate the pathogenesis and optimal management strategies for these coexisting hematologic malignancies.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Cellular Adaptation IV: Dysplasia and Metaplasia
Lineage Commitment

